Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Arena Pharmaceuticals, Inc.    ARNA

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Arena Pharmaceuticals, Inc. : Five Star Equities Issues New Research Reports on ARNA, DD, KR and VECO

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/17/2013 | 03:05pm CET

Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports.

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) shares hit a low of $7.70 Friday before settling to close at $7.78, a decrease of 6.71 percent. The stock traded in between $7.70 to $8.30 on volume of 8.97 million shares traded. Consumer Reports has recently advised their readers to ?skip? Arena?s weight loss drug, Belviq.

Get more information on Arena Pharmaceuticals and free access to the in-depth equity report at:
www.FiveStarEquities.com/ARNA

E I Du Pont De Nemours And Co (NYSE: DD) shares hit a low of $52.16 Friday before settling to close at $52.68, a decrease of 2.23 percent. The stock traded in between $52.16 to $53.70 on volume of 11.28 million shares traded. Jefferies Group currently has a ?hold? rating on the stock and has recently raised its price target on the company to $56.00 from $52.00.

Get more information on Du Pont and free access to the in-depth equity report at:
www.FiveStarEquities.com/DD

The Kroger Co. (NYSE: KR) hit a low of $34.67 Friday before settling to close at $34.79, a decrease of 0.77 percent. The stock traded in between $34.67 to $35.25 on volume of 2.46 million shares traded. Argus currently has a ?buy? rating on the stock and has recently raised its price target on the company to $40.00 from $34.00.

Get more information on Kroger and free access to the in-depth equity report at:
www.FiveStarEquities.com/KR

Veeco Instruments Inc. (NASDAQ: VECO) shares hit a low of $37.74 Friday before settling to close at $38.10, a decrease of 3.20 percent. The stock traded in between $37.74 and $39.04 on volume of 559,990 shares traded. UBS has reiterated it ?neutral? view on the company due to pricing pressure pricing pressure Veeco?s metal organic vapor deposition epitaxial systems.

Get more information on Veeco Instruments and free access to the in-depth equity report at:
www.FiveStarEquities.com/VECO

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Wall Street Fundamentals has no financial relationship with any company whose stock is mentioned in this release.

Contact:
Five Star Equities
info@fivestarequities.com


© Accesswire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ARENA PHARMACEUTICALS, INC
12/07 ARENA PHARMACEUTICALS : Completes Enrollment in Ralinepag Phase 2 Clinical Trial..
11/30 ARENA PHARMACEUTICALS ANNOUNCES FOUR : Crohn's & Colitis Foundation's Clinical a..
11/17 ARENA PHARMACEUTICALS : Reports Third Quarter 2016 Financial Results and Provide..
11/17 ARENA PHARMACEUTICALS : to Present at the 28th Annual Piper Jaffray Healthcare C..
11/09 ARENA PHARMACEUTICALS : to Present at the 28th Annual Piper Jaffray Healthcare C..
11/09 ARENA PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condit..
11/08 ARENA PHARMACEUTICALS INC. : (ARNA) is Trading Higher on Unusual Volume for Nove..
11/07 ARENA PHARMACEUTICALS : reports 3Q loss
11/07 ARENA PHARMACEUTICALS INC : Results of Operations and Financial Condition, Finan..
11/07 ARENA PHARMACEUTICALS : Reports Third Quarter 2016 Financial Results and Provide..
More news
Sector news : Biotechnology & Medical Research - NEC
12/03DJJOHNSON & JOHNSON : Boosts Actelion Bid -Bloomberg
12/02 Pharma execs weigh in on possible changes under Trump
11/30 ACTELION : Rejecting J&J could leave Actelion with 'lot of explaining to do'
11/28 Actelion's ambitious independent-minded CEO will drive up takeover price
11/26DJWHAT'S NEWS : Business & Finance -- WSJ
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
12/09 Healthcare bounces back from Trump tantrum
12/07 Arena Pharma completes enrollment in mid-stage ralinepag study in PAH; top-li..
11/29 Arena Pharmaceuticals' (ARNA) CEO Amit Munshi Presents at 28th Annual Piper J..
11/08 ARENA BEATS THE STREET : What Investors Need To Consider
11/07 Arena Pharmaceuticals' (ARNA) CEO Amit Munshi on Q3 2016 Results - Earnings C..
Advertisement
Financials ($)
Sales 2016 51,7 M
EBIT 2016 -72,8 M
Net income 2016 -82,8 M
Debt 2016 74,0 M
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales 2016 8,07x
EV / Sales 2017 10,1x
Capitalization 343 M
More Financials
Chart ARENA PHARMACEUTICALS, INC
Duration : Period :
Arena Pharmaceuticals, Inc Technical Analysis Chart | ARNA | US0400471027 | 4-Traders
Full-screen chart
Technical analysis trends ARENA PHARMACEUTI...
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 6
Average target price 3,75 $
Spread / Average Target 166%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Amit D. Munshi President, Chief Executive Officer & Director
Tina Susan Nova Chairman
Craig M. Audet SVP-Operations & Head-Global Regulatory Affairs
Kevin R. Lind Chief Financial Officer & Executive Vice President
John Adams Head-Scientific Affairs
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ARENA PHARMACEUTICALS,..-27.89%343
QUINTILES IMS HOLDINGS..14.10%19 286
INCYTE CORPORATION-7.21%18 957
CELLTRION, INC.--.--%9 997
LONZA GROUP AG9.20%9 261
SEATTLE GENETICS, INC.44.54%9 183
More Results